For the second time in less than three months, the FDA has determined that, because of data integrity issues discovered at a China-based medical device testing facility, the agency will reject all data from device studies conducted at the facility that are included in premarket device submissions until the firm adequately addresses the issues. According to the FDA, Suzhou, Ch... Read More